Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01437397 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,692
- Enrollment target
NCT01437397: Completed Phase 3 study, sponsored by AstraZeneca.
NCT01437397 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,692 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (119% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01437397, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,692 participants
- Enrollment target
Study Summary
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and the long-term safety and tolerability of the fixed dose combination. This study will include a 24 week treatment period, preceding by a run-in period, followed by a two week follow up visit. All patients will be randomized to one of four treatment arms or placebo.
Interventions
- DRUG Placebo
- DRUG Formoterol Fumarate
- DRUG Aclidinium Bromide
- DRUG Aclidinium Bromide/Formoterol Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,692 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
What the finished NCT01437397 record still lists
NCT01437397 is an interventional study that assigns participants to a tested intervention. Its 1,692 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (119% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01437397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01437397 about?
NCT01437397 is a clinical study titled "Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and the long-term safety and tole...
What is the current status of trial NCT01437397?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,692 participants. The study started on 2011-09. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01437397?
The interventions under investigation include: Placebo (DRUG), Formoterol Fumarate (DRUG), Aclidinium Bromide (DRUG), Aclidinium Bromide/Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT01437397?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01437397's enrollment target sits among peer trials
1,692 134th of 2000 higher than 1,867 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia